Electric vehicle maker Tesla announced earnings last week. The earnings call implies that the company faces a challenging road ahead. Read More

This maker of cannabis-infused medical treatments is a pre-clinical stage biotech with a small market cap. As such, it's a dangerous stock. But do the opportunities outweigh the risks? Read More

An examination of a marijuana "infrastructure play," its rivals, whether it's overpriced or underpriced, and a prediction for the stock in 2019. Read More

The last few years have been rough for biotech stocks, but Amgen has been a notable exception. It's now facing new threats from biosimilars. Can it continue to outperform? Read More

This mid-cap biotech is developing novel drugs for diseases that resist conventional therapies. Is Arena a future "rocket stock" or will it blow up on the launch pad? Read More

As these three blue chip stocks prove, sentiment moves the market in the short-term but fundamentals win out over the long-term. Read More

This cannabis biotech is a micro-cap garnering Wall Street's attention. As investors flock to pot investments, is United Cannabis an appealing play or risky penny stock? Read More

The best hotel stocks to own have plenty of cash to see them through the occasional rough patch without having to cut their dividends. Read More

Hemp (OTC: HEMP) uses the sturdy fibers of the hemp plant to create industrial products. Is this "picks-and-shovels" cannabis play a worthy investment or risky penny stock? Read More

This maker of cannabis-related recreational and medical products enjoys tailwinds as cannabis legalization continues apace. But is it an overly risky penny stock? Read More